News | February 12, 2015

ACC, Symphony Health Solutions Create New Cardiac Research Platform

Platform contains medical history of 5 million anonymized patients

February 12, 2015 – Symphony Health Solutions (SHS) and the American College of Cardiology announced the completion of a new research platform. The HIPAA-compliant platform combines anonymized patient-level data from the ACC's National Cardiovascular Data Registry (NCDR) with SHS's Integrated Dataverse, which includes prescription, medical and hospital claims. The newly integrated data includes approximately 5 million anonymized patients with up to six years of observed diagnoses, procedures, therapies and related findings.

Information from a large set of patients that is both broad in scope and deep in detail has, before now, been difficult to obtain — yet vital to improve care. The creation of a new analytical platform now enables a wide range of new analyses to help achieve that goal. The organizations will use the combined data sources to complete research projects focused on clinical outcomes, comparative effectiveness, therapy adoption and use, and population health, as well as additional studies and projects of interest. These analyses of patterns and treatments can ultimately improve care, enhance outcomes and reduce unnecessary healthcare costs.

"This analytic platform is ground-breaking in the level of data it will provide," said John S. Rumsfeld, M.D., Ph.D., FACC, chief science officer of the American College of Cardiology National Cardiovascular Data Registries. "The partnership between ACC and SHS brings together the detailed clinical data from the registries with the longitudinal data resources of SHS. This creates a synergy that can yield critical insights on improving cardiovascular care and patient outcomes."

Analytics solutions produced through the collaboration will have broad applicability across the healthcare market. Entities such as life sciences organizations and the government, with whom ACC and SHS engage today, will also benefit from the new research offerings.

For more information: www.symphonyhealth.com or www.acc.org

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Overlay Init